Retraction
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Paper Information
Record ID:
58036
Author(s):
Journal:
Publication Date:
September 04, 2015
Retraction Date:
October 22, 2024
(1.1 year years ago)
Subjects:
Institutions:
- LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Department of Hematology, Myeloma and Lymphoma Centre, Chang Zheng Hospital, The Second Military Medical University, Shanghai, China
- Sanofi Oncology, Cambridge, MA, USA
- Institute of Hematology, CAMS & PUMC, Tianjin, China
Countries:
Article Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1038/s41375-024-02443-zAdditional Notes:
see also: https://pubpeer.com/publications/BE119832A5B1091025C04244B43F5D
Citations (213)
213
Total Citations5
Post-Retraction(2.3%)
208
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
5
Within 1 year
0
After 2+ years
204
Days since retraction (latest)
Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy
Fuzhen Zhang, Yu Dong, Zeliang Yang et al. (9 authors)
International Immunopharmacology
Published: May 2025
204 days after retraction
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Akram N. Salah, Amr H. Hashem, Mohamed Bakr Zaki et al. (16 authors)
Journal of Biochemical and Molecular Toxicology
Published: Jan 2025
100 days after retraction
Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and <scp>PFS</scp> in myeloma: Development of a joint model using phase I/<scp>II</scp> data
Antoine Pitoy, Solène Desmée, François Riglet et al. (8 authors)
CPT Pharmacometrics & Systems Pharmacology
Published: Nov 2024
1 citation
1 citation
37 days after retraction
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Mingyuan Sun, Hongmei Jing, Qu Xiaoyan et al. (11 authors)
Scientific Reports
Open Access
Published: Nov 2024
20 days after retraction
CD38 as theranostic target in oncology
Valentina Bassareo, Jessica Bridoux, Puchowicz Michelle et al. (8 authors)
Journal of Translational Medicine
Open Access
Published: Nov 2024
6 citations
6 citations
14 days after retraction
Anti-Plasma Cell Antibodies: A New Era of HLA Antibody Control in Solid Organ Transplantation?
Sindhu Chandran, Flavio Vincenti
American Journal of Transplantation
Published: Oct 2024
2 citations
2 citations
21 days before retraction
Multiple myeloma: signaling pathways and targeted therapy
Qizhong Lu, Donghui Yang, Hexian Li et al. (5 authors)
Molecular Biomedicine
Open Access
Published: Jul 2024
24 citations
24 citations
110 days before retraction
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
Song Li, Dianze Chen, Yannan Yang et al. (19 authors)
Frontiers in Immunology
Open Access
Published: Jun 2024
1 citation
1 citation
119 days before retraction
Immunotherapy in Lung and Thoracic Cancer
Harun Muğlu, Ömer Fatih Ölmez
Unknown Journal
Published: Jun 2024
132 days before retraction
Paper citing SAR650984 directly induces multiple myeloma cell d...
Unknown Authors
Unknown Journal
Published: Jun 2024
132 days before retraction
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. (30 authors)
New England Journal of Medicine
Published: Jun 2024
86 citations
86 citations
141 days before retraction
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jérôme Lambert et al. (61 authors)
Nature Medicine
Open Access
Published: Jun 2024
40 citations
40 citations
141 days before retraction
Emerging trends and therapeutic applications of monoclonal antibodies
M. Janaki Ramaiah, Hari P. Nalluri, Prakash Narayana Reddy et al. (11 authors)
Gene
Published: May 2024
13 citations
13 citations
151 days before retraction
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda et al. (28 authors)
Cancer Immunology Immunotherapy
Open Access
Published: May 2024
158 days before retraction
Application of CD38 monoclonal antibody in kidney disease
Zhiyi Chen, Qianchun Xu, Zhangfei Shou
Frontiers in Immunology
Open Access
Published: May 2024
2 citations
2 citations
165 days before retraction
The numerous facets of 1q21<sup>+</sup> in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review)
Na Liu, Zhanzhi Xie, Hao Li et al. (4 authors)
Oncology Letters
Open Access
Published: Apr 2024
2 citations
2 citations
196 days before retraction
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel et al. (18 authors)
Haematologica
Open Access
Published: Feb 2024
6 citations
6 citations
264 days before retraction
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada et al. (13 authors)
Nature Medicine
Open Access
Published: Jan 2024
20 citations
20 citations
292 days before retraction
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
Flavio Vincenti, Oriol Bestard, Amarpali Brar et al. (19 authors)
Journal of the American Society of Nephrology
Open Access
Published: Dec 2023
17 citations
17 citations
301 days before retraction
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Niels W.C.J. van de Donk, Sonja Zweegman
Hematology/Oncology Clinics of North America
Published: Dec 2023
7 citations
7 citations
301 days before retraction
Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
Yu. E. Ryabukhina, P. A. Zeynalovа, F. M. Abbasbeyli et al. (7 authors)
Oncohematology
Open Access
Published: Dec 2023
1 citation
1 citation
319 days before retraction
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
Kazuhito Suzuki, Shingo Yano
Life
Open Access
Published: Nov 2023
1 citation
1 citation
337 days before retraction
Immunomodulatory properties of <scp>CD38</scp> antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Bisht, Taro Fukao, Marielle Chiron et al. (9 authors)
Cancer Medicine
Open Access
Published: Oct 2023
26 citations
26 citations
387 days before retraction
New Biological Therapies for Multiple Myeloma
Alfred L. Garfall
Annual Review of Medicine
Published: Sep 2023
17 citations
17 citations
398 days before retraction
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
Olivia Perez de, Lauren T. Reiman, David Jayabalan et al. (14 authors)
Blood Advances
Open Access
Published: Aug 2023
21 citations
21 citations
418 days before retraction
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Façon, Philippe Moreau, Ross Baker et al. (12 authors)
Haematologica
Open Access
Published: Aug 2023
11 citations
11 citations
433 days before retraction
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study
Bernard Regidor, Scott Jew, Marissa‐Skye Goldwater et al. (11 authors)
European Journal Of Haematology
Published: Jul 2023
2 citations
2 citations
456 days before retraction
Isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel et al. (18 authors)
Research Square (Research Square)
Open Access
Published: Jul 2023
468 days before retraction
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Enrique M. Ocio, Aurore Perrot, Pierre Bories et al. (21 authors)
Leukemia
Open Access
Published: Jun 2023
20 citations
20 citations
496 days before retraction
Improving immunotherapeutic treatment strategies for relapsed/refractory multiple myeloma patients
Kristine A. Frerichs
Unknown Journal
Open Access
Published: May 2023
531 days before retraction
Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
Lijie Xing, Yuntong Liu, Jiye Liu
Cancers
Open Access
Published: Apr 2023
12 citations
12 citations
560 days before retraction
Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Anlai Wang, Zhili Song, Gang Zheng et al. (11 authors)
Unknown Journal
Open Access
Published: Apr 2023
568 days before retraction
Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Anlai Wang, Zhili Song, Gang Zheng et al. (11 authors)
Unknown Journal
Open Access
Published: Apr 2023
568 days before retraction
Supplementary Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Lijie Xing, Su Wang, Jiye Liu et al. (16 authors)
Unknown Journal
Open Access
Published: Mar 2023
571 days before retraction
Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Lijie Xing, Su Wang, Jiye Liu et al. (16 authors)
Unknown Journal
Open Access
Published: Mar 2023
571 days before retraction
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients
Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara et al. (7 authors)
CPT Pharmacometrics & Systems Pharmacology
Open Access
Published: Mar 2023
2 citations
2 citations
571 days before retraction
Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg
Sigrid De Wilde, Laurent Plawny, Guy Berchem
Hematology
Open Access
Published: Mar 2023
1 citation
1 citation
595 days before retraction
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Alexander M. Lesokhin, Richard LeBlanc, Meletios Α. Dimopoulos et al. (21 authors)
Cancer Medicine
Open Access
Published: Mar 2023
8 citations
8 citations
599 days before retraction
Targeting lysosomal HSP70 induces acid sphingomyelinase‐mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies
Yingjie Qing, Yongjian Guo, Qin-Wen Zhao et al. (12 authors)
Clinical and Translational Medicine
Open Access
Published: Mar 2023
7 citations
7 citations
601 days before retraction
Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Parva Bhatt, Colin Kloock, Raymond L. Comenzo
Current Oncology
Open Access
Published: Feb 2023
51 citations
51 citations
615 days before retraction
Increased expression of <scp>CEP72</scp> predicts poor prognosis in multiple myeloma
Dan Guo, Jinfeng Lu, Hao Ji et al. (7 authors)
International Journal of Laboratory Hematology
Published: Feb 2023
1 citation
1 citation
617 days before retraction
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
Fabiola De Luca, Alessandro Allegra, Carla Di Chio et al. (6 authors)
International Journal of Molecular Sciences
Open Access
Published: Feb 2023
15 citations
15 citations
625 days before retraction
Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Joshua Richter, Peggy L. Lin, Viviana García-Horton et al. (8 authors)
Cancer Medicine
Open Access
Published: Feb 2023
7 citations
7 citations
629 days before retraction
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Amaia Etxebeste
Unknown Journal
Open Access
Published: Jan 2023
660 days before retraction
The Role of Cathepsin B in Pathophysiologies of Non-tumor and Tumor tissues: A Systematic Review
Jiangping Wang, Minying Zheng, Xiaohui Yang et al. (5 authors)
Journal of Cancer
Open Access
Published: Jan 2023
34 citations
34 citations
660 days before retraction
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
Danilo De Novellis, Raffaele Fontana, Valentina Giudice et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Dec 2022
23 citations
23 citations
662 days before retraction
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Mariana Tannoury, Delphine Garnier, Santos A. Susín et al. (4 authors)
Cancers
Open Access
Published: Dec 2022
9 citations
9 citations
685 days before retraction
Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study
Kazutaka Sunami, Shin‐ichi Fuchida, Kenshi Suzuki et al. (20 authors)
Hematological Oncology
Open Access
Published: Nov 2022
1 citation
1 citation
696 days before retraction
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Matthew Ho, Alexander Xiao, Dongni Yi et al. (5 authors)
Current Oncology
Open Access
Published: Nov 2022
19 citations
19 citations
701 days before retraction
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G. Martin, Marcelo Capra, Mohamad Mohty et al. (14 authors)
Transplantation and Cellular Therapy
Open Access
Published: Nov 2022
3 citations
3 citations
711 days before retraction
Quick Stats
Total Citations:
213
Years Since Retraction:
1.1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025